Researchers built an E. coli-based system combining surface display and co-culture to produce, modify, and screen antimicrobial peptides with over 90% display efficiency.
>90% display efficiencyThe E. coli surface display system using Lpp-OmpA and Omp1 achieved over 90% efficiency for presenting modified antimicrobial peptides for screening
What the researchers found
The researchers successfully combined E. coli surface display with co-culture techniques to produce intracellularly modified RiPPs (ribosomally synthesized and post-translationally modified peptides) extracellularly. A brevicidine-mimicking mutant peptide was modified intracellularly by two enzymes — OspR (introducing ornithine residues) and SyncM (introducing a methyllanthionine ring) — then displayed on the E. coli surface using Lpp-OmpA and Omp1 proteins.
In a co-culture with separate E. coli cells displaying the leader peptidase LahT150 (via the ice nucleating protein InaK), the modified peptide was successfully cleaved and detected in the culture supernatant, where its antimicrobial activity was confirmed. Surface display efficiency exceeded 90% using the Lpp-OmpA and Omp1 systems.
Why it matters
Finding new antibiotics is urgent but difficult, especially for complex modified peptides that can't be easily screened through traditional genetic libraries. This platform bridges a key gap: it allows gene-encoded production and modification of peptides that mimic non-ribosomal peptide structures — previously very difficult to screen at scale. With over 90% display efficiency and proven antimicrobial activity detection, it could significantly speed up the discovery of next-generation peptide antibiotics.
How the study worked
The platform used two populations of E. coli in co-culture. The first population expressed a precursor peptide that was modified intracellularly by RiPP-modifying enzymes (OspR for ornithine incorporation, SyncM for methyllanthionine ring formation) and then displayed on the cell surface via Lpp-OmpA or Omp1 fusion proteins. The second population displayed the leader peptidase LahT150 on its surface via the InaK ice nucleating protein. When co-cultured, the peptidase cleaved the displayed modified peptide, releasing it into the supernatant for activity testing. Display efficiency was quantified using flow cytometry or related surface detection methods.
What this study cannot tell us
The study demonstrated proof-of-concept with a single brevicidine-mimicking peptide variant. Scalability to large mutant libraries has not been shown. The antimicrobial activity assessment was basic — detailed MIC values against diverse pathogens were not reported in the abstract. The co-culture system's performance may vary with different peptide sizes and modification types. Industrial-scale application feasibility remains to be determined.
How to read the evidence
This is a proof-of-concept methodology study demonstrating a new screening platform. While it successfully produced and detected a modified antimicrobial peptide, it has not yet been validated for large-scale library screening or applied to discover novel antibiotics.
When this study was published
Published in 2026, this is a very recent study reflecting the current state of synthetic biology and RiPP engineering approaches to antimicrobial peptide discovery.
The bigger picture
The antimicrobial peptide field has long faced a bottleneck: natural non-ribosomal peptides are powerful antibiotics but are hard to engineer because they aren't gene-encoded. RiPP-based systems offer a workaround by using gene-encoded peptides with enzymatic modifications that can mimic NRP structures. This platform advances the field by enabling rapid screening of these modified peptides directly in E. coli, potentially opening the door to high-throughput discovery of new antibiotics.
Questions still open
- Can this platform be scaled to screen large libraries of thousands or millions of modified peptide variants simultaneously?
- How broadly applicable is this system — can it accommodate other types of post-translational modifications beyond ornithine and methyllanthionine?
- Could this approach be automated for high-throughput discovery of novel antimicrobial peptides against specific drug-resistant pathogens?
Common questions
What are RiPPs and why are they important for antibiotic discovery?
How does the surface display and co-culture system work?
Read the original research
A screening platform in Escherichia coli for modified antimicrobial peptide by combining surface display and co-culture.
Microbiological research, 307, 128484
Citation
Xu, Yanli; Kuipers, Oscar P. (2026). A screening platform in Escherichia coli for modified antimicrobial peptide by combining surface display and co-culture.. Microbiological research, 307, 128484. https://doi.org/10.1016/j.micres.2026.128484